Clinical trials: Medication Interaction
Healthy
A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
The primary objectives of this study are to determine the effect of multiple doses of ALXN2080 on the single-dose PK of rosuvastatin and to determine the effect of multiple doses of ALXN2080 on the single-dose PK of metformin.
- Trial name
- NCT06160414
- Testing
- Metformin, Rosuvastatin, ALXN2080
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Advanced Solid Tumor
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2#VEGFR-2#, Induces Transporter Pgp function in vitro.
- Trial name
- NCT04322552
- Testing
- Apatinib Mesylate, Digoxin tablet
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers
This study will determine the effect of acidic drugs such as proton-pump inhibitors on the pharmacokinetics of Vatalinib under fasting and fed conditions.
- Trial name
- NCT00426452
- Testing
- Vatalinib
- Volunteers
- 24 people
- Sponsor
- Novartis
Pharmacokinetics of YM178
Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.
- Trial name
- NCT00776516
- Testing
- mirabegron, rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy Participants
A Study to Assess the Effects of BPN14770 on Rosuvastatin
The primary objective of this study is to investigate the effects of BPN14770 on the pharmacokinetics of the breast cancer resistance protein and organic anion transporting polypeptide 1B1 substrate rosuvastatin in healthy adults.
- Trial name
- NCT07011992
- Testing
- Rosuvastatin, BPN14770
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shionogi
Healthy
Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers
The purpose of this study is to evaluate the drug-drug interaction between Erdosteine and Bepotastine besilate in healthy adult volunteers.
- Trial name
- NCT02332044
- Testing
- Erdos, Talion, Erdos, Talion
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy, Pharmacokinetics of ASP1941
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects
The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and pioglitazone hydrochloride in multiple and single doses.
- Trial name
- NCT01088919
- Testing
- ASP1941, pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Hypertension
Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension
The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.
- Trial name
- NCT00548067
- Testing
- Valsartan/hydrochlorothiazide (HCTZ), Valsartan/amlodipine, Amlodipine/hydrochlorothiazide(HCTZ)
- Where
- 5 sites in India
- Volunteers
- 111 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
This is a randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of DA-1229 5 mg and Metformin IR 1000 mg after oral administration in…
- Trial name
- NCT01941199
- Testing
- DA-1229, metformin, DA-1229 + metformin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib
GSK3915393 is a new medicine which is being developed for a chronic lung disease called Idiopathic Pulmonary Fibrosis (IPF). This is a healthy participant study which has two parts.
- Trial name
- NCT06625489
- Testing
- Nintedanib, GSK3915393
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Opioid Use
Buprenorphine-Fentanyl Interaction Study
An increase in overdose deaths has been attributed to widespread access to fentanyl and carfentanyl. The study is designed to determine if buprenorphine can change the respiratory depression response to intravenous (IV) fentanyl.
- Trial name
- NCT03747341
- Testing
- Buprenorphine Injectable Solution - Part A, Fentanyl - Part A, Ondansetron - Parts A + B
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Drug Interaction Study
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and…
- Trial name
- NCT02807051
- Testing
- Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Drug Drug Interaction
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects
- Trial name
- NCT05574374
- Testing
- DWP14012, DWC202202, DWC202203
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
HIV
DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate
This trial will investigate the potential drug-drug interaction between dapivirine vaginal Ring-004 and vaginally administered miconazole nitrate, and will evaluate the safety of co-administration of the dapivirine vaginal ring…
- Trial name
- NCT01731574
- Testing
- dapivirine, miconazole
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Male Volunteers
Pharmacokinetic Drug Interaction Study in Healthy Male Subjects
A Randomized, Open Label, Drug-Drug interaction study to investigate effect of ketoconazole or rifampicin on the Pharmacokinetic characteristics and safety of LC15-0444 in Healthy Male Volunteers.
- Trial name
- NCT01426906
- Testing
- Ketoconazole, rifampicin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy Volunteer
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
- Trial name
- NCT06698926
- Testing
- ABBV-CLS-616, Itraconazole
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AbbVie
Phase 1
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
The study is a monocentric, open label, phase 1 study to evaluate the pharmacokinetics, and in particular the dose proportionality of setanaxib and its metabolites after a single oral dose (400 mg, 800 mg, 1200 mg, and 1600 mg)…
- Trial name
- NCT04327089
- Testing
- Setanaxib
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Calliditas Therapeutics AB
Healthy Subjects, Drug-drug Interaction
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
- Trial name
- NCT04459598
- Testing
- Efavirenz, Quizartinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Nausea and Vomiting, Chemotherapy-Induced
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V.
- Trial name
- NCT00440128
- Testing
- Docetaxel, Casopitant/Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline